Loading news...
EIKN (NASDAQ: EIKN - Get Free Report) has received an average rating of "Moderate Buy" from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average
Stock News Novo sues Hims over compounded weight-loss drugs: Novo Nordisk (NVO) filed suit to stop Hims and Hers Health (HIMS) from selling compounded semaglutide
Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings. Five IPOs are currently scheduled in the week ahead, and some smaller issuers may join the calendar throughout the week.
Stock News Amazon lifts 2026 capex to ~$200B: Amazon (AMZN) posted a Q4 EPS miss but revenue beat and guided 2026 capital expenditures to about $200 billion, pr
Shares of drug developer Eikon Therapeutics opened 5.28% below their offer price in their Nasdaq debut on Thursday, valuing the company at about $860.3 million.
Drug developer Eikon Therapeutics said on Wednesday it had raised $381.2 million in its U.S. initial public offering, selling about 21.2 million shares priced at $18 apiece.
U.S. IPO Weekly Recap: Trio Of Sizable Listings Underwhelm To Close Out January
Drug developer Eikon Therapeutics said on Wednesday it was targeting a valuation of up to $908.2 million in its U.S. initial public offering, as biotech listings make a comeback.
Eikon Therapeutics, Inc. is pursuing an IPO to fund its oncology pipeline, led by EIK1001 in Phase 2 trials for melanoma and NSCLC. EIKN's initial EIK1001 data show a 60% response rate, limited adverse events, and no dosing limitations, supporting continued clinical advancement. Backed by substantial venture capital and led by top-tier pharma executives, EIKN is well capitalized for near-term milestones in 2026.
Clinical biopharmaceutical company Eikon Therapeutics on Friday filed for an initial public offering in the United States.